Harvey Berger

Harvey and Chrysanthi Berger have supported the Palm Beach Day Academy and the American Cancer Society. In February 2018, Berger was appointed to the Dana-Farber Cancer Institute Board of Trustees, the governing board of the organization.

In February 2017, Medinol, Inc. announced that Berger would be serving as its executive chairman. On the global management team, his focuses at Medinol would include business management, global strategy, new business and technology initiatives, as well as improving operational efficiency as the company expands worldwide. Berger's role at Medinol was said to include working with their core business of interventional cardiovascular devices, along with its new businesses developing percutaneous aortic valves, sub-millimeter implantable sensors, and related products.

At the end of 2015, Berger retired from ARIAD and became an advisor to the board of directors. In early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of Takeda Oncology.

In 2013, Berger was awarded the Ernst & Young Entrepreneur of the Year Award for the New England Region. The award recognizes success in innovation, financial performance, personal commitment to their business communities and other areas.

In 2000, Berger focused ARIAD on oncology, based on recent discoveries in the human genome. Under Berger's leadership, ARIAD grew to over 365 employees and established a European headquarters in Lausanne, Switzerland.

In 1991, Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts. He served as chairman and CEO from 1991 to 2015. In 1992, ARIAD raised $46 million, the largest single round of financing for a startup in the biotechnology industry at the time. ARIAD's plan was to develop drugs that would interfere with communication signals within cells, rather than on the cell surface or in between cells. In 1994, ARIAD filed for an initial public offering and was listed on the NASDAQ market.

From 1986 until 1991, Berger held executive management positions at Centocor, Inc. including executive vice president and president of the Research and Development Division. He led the development of Remicade® (infliximab), formerly known as Centara, a drug for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and rheumatoid arthritis, ReoPro® (abciximab), formerly known as CentoRx, a drug for the prevention of ischemic complications in patients with CAD undergoing percutaneous interventions, and the cancer diagnostic test, CA125, to evaluate patients with ovarian cancer.

Berger received his B.A. in Biology from Colgate University in 1972 and received his M.D. from Yale School of Medicine in 1977. He completed further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.